Tamoxifen‐treated breast carcinoma patients and the risk of acute myocardial infarction and newly‐diagnosed angina
Explore this paper's citation graph
Summary
It is known that tamoxifen therapy favorably affects blood cholesterol levels and other cardiovascular disease risk factors, but few studies to date have reported a lower risk of heart disease for breast carcinoma patients who are treated with tamoxIFen.
- Type
- article
- Published
- 2005-03-15
- Cited by
- 64
- References
- 72
- OpenAlex
- https://openalex.org/W1973599381
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21162162
Keywords
Medicine, Tamoxifen, Breast cancer, Internal medicine, Myocardial infarction
References
- The structural mimicry of membrane sterols by tamoxifen: evidence from cholesterol coefficients and molecular-modelling for its action as a membrane anti-oxidant and an anti-cancer agent.
- Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.
- The incidence of breast cancer in the General Practice Research Database compared with national cancer registration data
- Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.
- Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
- Use of the UK General Practice Research Database for pharmacoepidemiology.
- Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen?
- Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial.
- Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity.
- A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
- Tamoxifen reduces plasma homocysteine levels in healthy women.
- Tamoxifen decreases lipoprotein (a) in patients with breast cancer.
- Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction.
- Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
- A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes.
- Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer
- Quality of non-breast cancer health maintenance among elderly breast cancer survivors.
- Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.
Cited by
- Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
- Risikoadaptierte Hormontherapie des primär operablen Mammakarzinoms
- Survivors of adult cancer – their use of primary care services and unmet needs
- From cancer patient to cancer survivor : lost in transition
- A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
- Nachsorge beim Mammakarzinom
- Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
- Bone Health and Coronary Heart Disease in Postmenopausal Women with Breast Cancer Treated with Tamoxifen: A Dissertation
- Effect of OS-0544, a selective estrogen receptor modulator, on endothelial function and increased sympathetic activity in ovariectomized rats.
- Estrogens and SERMs in coronary heart disease.
- Toremifene: an evaluation of its safety profile.
- Safety of Adjuvant Endocrine Therapy in Postmenopausal Women With Breast Cancer
- Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study
- Exploring the use of the survivorship consult in providing survivorship care
- Tamoxifen: important considerations of a multi-functional compound with organ-specific properties.
- Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use.
- Tamoxifen Treatment in Danish Breast Cancer Patients and 5-Year Risk of Arterial Atherosclerotic Events: A Null Association
- Translating trial data into patients benefits: making the right choice.
- Estrogen-Mediated Protection in Myocardial Ischemia-Reperfusion Injury
- Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials.
Related papers
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide
- Sensitivity and insensitivity of breast cancer to tamoxifen.
- Tamoxifen stimulates in vivo growth of drug-resistant estrogen receptor-negative breast cancer
- Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats
- Effectiveness of steroid and imidazole drugs in inhibiting aromatase activity
- Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance
- Reduced tamoxifen accumulation is not associated with stimulated growth in tamoxifen resistance
- Tamoxifen and its new derivatives in cancer research.
- D122. The Impact of Tamoxifen Therapy on Thrombotic Flap Complications: A Nationwide Analysis
- EDITORIALS Is Low-Dose Tamoxifen Useful for the Treatment and Prevention of Breast Cancer?